Has Pooja Patel, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,771 in general payments to Pooja Patel, MD across 271 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Pooja Patel, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Pooja Patel, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Pooja Patel, MD

Neurology · Boca Raton, FLNPI 1740555945

Payments from drug & device makers

$7,771in general payments, 2019–2025

Across 271 payments — averaging $28.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Neuropace, Inc.$2K
AbbVie$821
UCB, Inc.$711
EMD Serono, Inc.$448
Abbott$433
Acadia Pharmaceuticals Inc$335
plus $3K from 36 others

What the payments were for

Speaking & faculty fees$701%
Travel & lodging$89111%
Food & beverage$6,81088%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Neuropace, Inc.	14	$1,947
AbbVie(2 entities)	40	$821
UCB, Inc.	17	$711
EMD Serono, Inc.	27	$448
Abbott	15	$433
Acadia Pharmaceuticals Inc	23	$335
Amgen	10	$319
Pfizer	11	$258
SK Life Science, Inc.	7	$254
Neurelis, Inc.	8	$229
AstraZeneca	10	$191
Eisai Inc.	8	$175
CSL Behring	8	$159
Novartis	10	$158
Greenwich Biosciences, Inc.	6	$123
Biogen	2	$117
Acorda Therapeutics, Inc	5	$105
Teva Pharmaceuticals USA, Inc.	5	$88
Sanofi	5	$87
E.r. Squibb & Sons, L.L.C.	4	$76
Biosense Webster, Inc.	1	$67
Argenx US, Inc.	2	$66
Sunovion Pharmaceuticals Inc.	3	$57
Jazz Pharmaceuticals Inc.	2	$57
Catalyst Pharmaceuticals, Inc.	3	$53
Takeda Pharmaceuticals U.S.A., Inc.	2	$48
MDD US Operations, LLC	2	$40
Zimmer Biomet	2	$38
Aquestive Therapeutics, Inc.	2	$35
Bristol Myers Squibb	2	$33
Alnylam Pharmaceuticals Inc.	2	$33
Tanabe Pharma America, Inc.	2	$32
Integra Lifesciences Corporation	1	$31
Neurocrine Biosciences, Inc.	2	$28
Akcea Therapeutics, Inc.	1	$17
Assertio Therapeutics, Inc.	1	$17
Aprecia Pharmaceuticals, LLC	1	$16
Springworks Therapeutics, Inc.	1	$15
Avanir Pharmaceuticals, Inc.	1	$15
Merz North America, Inc.	1	$14
Grifols USA, LLC	1	$13
Boston Scientific	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,771 in reported general payments places this provider in the 60th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida →

Medicare billing

Part B allowed, 2024

$824,776

Medicare patients

832

Services billed

66,457

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Lacosamide	24	$4,821
Levetiracetam	68	$1,769
Memantine Hcl	51	$1,705
Rivastigmine	11	$1,629
Oxcarbazepine	14	$929
Donepezil Hcl	61	$613
RizatriptanRizatriptan Benzoate	40	$593
Lamotrigine	30	$580
Gabapentin	35	$500
Pantoprazole Sodium	12	$420
Primidone	14	$227
Amitriptyline Hcl	29	$224
Topiramate	12	$185
Pregabalin	17	$133
Tizanidine Hcl	16	$103

Paid to pharmacies, not to this prescriber.

Other neurology in Boca Raton

Stuart IsaacsonBoca Raton$10.5M
Brian SteingoBoca Raton$4.6M
Marc FeinbergBoca Raton$3.2M
Mark GoldsteinAtlantis$36.1M
Derrick RobertsonTampa$27.6M
Beth SafirsteinHallandale Beach$25.7M
Michael PfefferMiami$24.5M
Mark BrodyDelray Beach$20.5M
Paayal PatelWest Palm Beach$17.3M
Wendy BondFort Myers$14.7M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →